Gemelli Biotech

Executive Summary

Gemelli Biotech is a San Diego-based diagnostics company specializing in non-invasive precision tests for gastrointestinal diseases, including SIBO, IMO, excess hydrogen sulfide, and post-infectious IBS. Founded in 2018, the company leverages microbiome biology to develop clinically validated biomarkers that enable definitive detection and optimal treatment of common yet underdiagnosed GI conditions. With a focus on addressing the growing demand for microbiome-based diagnostics, Gemelli's products aim to replace traditional breath tests and invasive procedures. The company operates in a competitive but expanding market, driven by rising awareness of gut health and the microbiome's role in disease. While still private and early-stage, Gemelli's targeted approach and strong scientific foundation position it for potential growth through regulatory clearances, commercial partnerships, and expanded test menus.

Upcoming Catalysts (preview)

• Q2 2026FDA clearance or CLIA waiver for flagship SIBO/IMO breath test60% success
• Q3 2026Strategic partnership with large GI clinic network or diagnostic lab50% success
• Q4 2026Publication of clinical validation study for hydrogen sulfide test70% success